Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Equity Average (2016 - 2025)

Corcept Therapeutics' Equity Average history spans 10 years, with the latest figure at $639.9 million for Q4 2025.

  • For Q4 2025, Equity Average fell 2.94% year-over-year to $639.9 million; the TTM value through Dec 2025 reached $639.9 million, down 2.94%, while the annual FY2025 figure was $663.7 million, 11.89% up from the prior year.
  • Equity Average for Q4 2025 was $639.9 million at Corcept Therapeutics, up from $633.8 million in the prior quarter.
  • Across five years, Equity Average topped out at $681.4 million in Q1 2025 and bottomed at $391.8 million in Q1 2022.
  • The 5-year median for Equity Average is $516.9 million (2021), against an average of $534.7 million.
  • The largest annual shift saw Equity Average fell 24.23% in 2022 before it surged 39.83% in 2024.
  • A 5-year view of Equity Average shows it stood at $458.0 million in 2021, then rose by 6.46% to $487.6 million in 2022, then fell by 0.7% to $484.2 million in 2023, then skyrocketed by 36.15% to $659.2 million in 2024, then dropped by 2.94% to $639.9 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Equity Average are $639.9 million (Q4 2025), $633.8 million (Q3 2025), and $659.5 million (Q2 2025).